Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
Nanox (NASDAQ: NNOX), a medical imaging technology company, has scheduled its first quarter 2025 financial results announcement for May 22, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, who will discuss the quarterly results and provide a business update.
Nanox (NASDAQ: NNOX) has received FDA 510(k) clearance for its new Nanox.ARC X multi-source digital tomosynthesis system. The clearance, obtained in under 30 days, allows for general use tomographic imaging, including musculoskeletal, pulmonary, intra-abdominal, and paranasal indications in adult patients.
The system features Nanox's proprietary digital Nanox.SOURCE and advanced tomosynthesis technology with cold cathode, enabling enhanced 3D body visualization. Key improvements include:
- Streamlined single-unit design with reduced footprint
- 'Plug and play' one-day installation
- Standard power operation (110v/230v 16A)
- Cables-free design for improved safety and maintenance
The company plans to offer the Nanox.ARC X alongside the current Nanox.ARC later this year, expanding its product portfolio.
Nanox (NASDAQ: NNOX) reported Q4 2024 financial results and business updates. The company generated $3.0 million in revenue, up from $2.4 million in Q4 2023. Key achievements include FDA clearance for Nanox.ARC general use and CE mark approval in the EU.
Financial highlights: Net loss increased to $14.1 million compared to $10.2 million in Q4 2023. The company reported a gross loss of $2.9 million. Cash position stood at $83.5 million as of December 31, 2024.
Business developments include new partnerships with Ezra AI Inc. for cancer detection screening and expansion into EU markets through distributors in Romania and Greece. The company raised approximately $37.8 million through the sale of 5.0 million ordinary shares in Q4 2024.
Nanox (NASDAQ: NNOX) announced that its subsidiary Nanox AI will present new data from the ADOPT study at four major medical conferences across Europe from March to June 2025. The study, completed in February 2025, evaluated HealthVCF at four NHS trusts in the UK.
Key findings show that HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new asymptomatic patients with vertebral compression fractures - up to six times more than the national NHS average. The AI-enabled Fracture Liaison Services demonstrated up to 10% reduction in patient refracture rates and cost savings of up to £50,000 per healthcare organization.
The company's newer FDA-cleared solution, HealthOST, offers improved fracture measurement precision and can detect low bone mineral density in routine CT scans without additional imaging or radiation exposure.
Nanox (NASDAQ: NNOX), a medical imaging technology company, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for March 31, 2025, before market open. The company will host a conference call at 8:30 a.m. ET featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel to discuss the results and provide a business update.
Nanox (NASDAQ: NNOX) will present new clinical data for its Nanox.ARC digital tomosynthesis system at ECR 2025 in Vienna. The system recently received both CE mark certification for European marketing and FDA 510(k) clearance in December 2024.
Three key studies will be presented:
- A 19-patient clinical study showing diagnostic value in 17 cases for fracture detection
- A phantom study demonstrating superior lung nodule detection in simulated obesity conditions compared to standard X-ray
- A case series highlighting improved musculoskeletal imaging applications
The Nanox.ARC system features a proprietary digital X-ray source with cold cathode technology, providing 3D body views while reducing radiation exposure and reading time. Clinical results showed enhanced detection of occult fractures, improved cast imaging, and potential reduction in CT scan requirements.
Nanox has received CE mark certification for its Nanox.ARC imaging system and Nanox.CLOUD infrastructure, enabling marketing in the European market. This follows the system's recent FDA clearance for general use in the U.S.
The Nanox.ARC is a stationary X-ray system that generates tomographic images using a proprietary digital X-ray source with cold cathode technology. It creates comprehensive 3D views of the body, enhancing visualization with multiple image layers while reducing structure super-imposition common in 2D X-rays.
Currently, there are dozens of units in various stages of shipment and deployment globally. The company will present new clinical data supporting Nanox.ARC usage at the European Congress of Radiology (ECR) 2025.
Nanox (NASDAQ: NNOX) has received FDA 510(k) clearance for its Nanox.ARC imaging system for general use, including pulmonary, intra-abdominal, and paranasal sinus indications, expanding from its previous musculoskeletal system clearance. The system features proprietary digital X-ray technology with cold cathode tomosynthesis, providing enhanced 3D visualization compared to traditional 2D X-rays.
The Nanox.ARC is currently deployed across seven U.S. states, with dozens of units in various stages of deployment worldwide. The system is designed for professional healthcare facilities and operated by trained medical professionals. It offers potential benefits including reduced patient wait times, faster diagnosis, and improved workflow integration, while requiring less space and power than traditional X-ray machines.